Neurotech International Ltd
ASX:NTI
Neurotech International Ltd
Neurotech International Ltd. engages in the research, designing, marketing, and through third party manufacturers, production of wearable neurotechnology devices to assist with neurological conditions such as autism. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm operates through its wholly owned, Malta-based subsidiary AAT Research Limited. The firm is focusing on neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI/Dolce cannabis strains. The firm through its class II device Mente is focused on development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is, a home therapy that is clinically proven to increase engagement and relaxation in autistic children with elevated Delta band brain activity.
Neurotech International Ltd. engages in the research, designing, marketing, and through third party manufacturers, production of wearable neurotechnology devices to assist with neurological conditions such as autism. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm operates through its wholly owned, Malta-based subsidiary AAT Research Limited. The firm is focusing on neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI/Dolce cannabis strains. The firm through its class II device Mente is focused on development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is, a home therapy that is clinically proven to increase engagement and relaxation in autistic children with elevated Delta band brain activity.
